FRE Fresenius SE & Co. KGaA

55.50USD50.49 EUR · XETRA-2.49%Mkt Cap: 32.06B USDP/E: 18.36

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fr…

Institutional holders12 on file

Key Statistics

Company
Market Cap32.06B USD
Enterprise Value43.46B USD
Revenue (TTM)25.95B USD
Gross Profit6.26B USD
Net Income (TTM)1.39B USD
Revenue/Share46.08 USD
Last Price55.50 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees179.5K
CountryDE
SectorHealthcare
IndustryMedical Care Facilities
ISINDE000FRE5EN2
Valuation
P/E (Trailing)18.36
P/E (Forward)13.24
PEG0.95
EV/EBITDA12.76
EV/Revenue1.67
P/S1.24
P/B1.42
EPS (TTM)3.10 USD
EPS (Forward)4.30 USD
52W Range
38.5979% of range60.06
52W High60.06 USD
52W Low38.59 USD
Profitability
Gross Margin24.89%
Oper. Margin9.93%
EBITDA Margin13.12%
Profit Margin5.53%
ROE6.62%
ROA3.05%
ROIC5.27%
ROCE6.61%
Growth
Revenue Growth5.90%
Earnings Growth6.50%
Cash Flow & Leverage
Operating CF2.83B USD
CapEx (TTM)1.65B USD
FCF Margin1.49%
FCF Yield1.21%
Net Debt11.13B USD
Net Debt/EBITDA3.27
Net Debt/FCF28.70
Balance Sheet
Debt/Equity0.62
Current Ratio1.52
Quick Ratio0.82
Book Value/Sh40.03 USD
Cash/Share3.35 USD
Dividends
Fwd Div Rate1.15 USD
Trail. Div Rate1.15 USD
Div. Yield1.95%
5Y Avg Yield2.79%
Payout Ratio37.23%
Ex-Div DateMay 25, 2026
Pay Date—
Splits
Last Split3:1
Split DateAug 4, 2014
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)63.97 USD
Upside (mean)+15.3%
Target Range57.16 USD – 71.45 USD
57.16+15.3% to mean71.45
# Analysts14
Ownership
Shares Out.563.24M
Float410.56M
Insiders27.00%
Institutions45.16%
Technical
SMA 5051.54 (+7.7%)
SMA 20048.67 (+14.0%)
Beta0.77
S&P 52W Chg12.00%
Avg Vol (30d)968.31K
Avg Vol (10d)1.05M
Technical Indicators
RSI (14)61.4
MACD2.0545
MACD Signal2.0403
MACD Hist.+0.0143
BB Upper62.20 USD
BB Middle55.59 USD
BB Lower48.99 USD
BB Width23.75%
ATR (14)1.259 USD
Vol Ratio (20d)1.12x

About Fresenius (ETR: FRE)

›

Fresenius (ETR: FRE) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 179,493 employees.

The shares were at 50.49 EUR on 20 November 2026, up 6.0% over 52 weeks. Its 52-week range is 35.11 EUR to 54.64 EUR: the price is 7.6% below the high and 43.8% above the low.

At a market capitalisation of 29.16B EUR, it trades at 18.4 times trailing earnings and 13.2 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.7, a discount of 22% for FRE. It pays a dividend yielding 1.95% (it pays out 37% of its earnings), against a median of 0.66% among the dividend payers in that peer group.

Fresenius reports return on equity of 6.6%, an operating margin of 9.9% and revenue up 5.9% year over year.

Its debt exceeds its cash by 10.12B EUR, a debt-to-equity ratio of 0.62. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 58.19 EUR is 15.3% above the current price. The next earnings report is expected on 24 February 2027.